The Unraveling of Chemours: Material Weakness Causes Stock to Plummet

Chemours’ Downward Spiral

Chemours, traded on the NYSE under the symbol CC, witnessed a catastrophic decline of nearly 11% in after-hours trading on Wednesday. This nosedive occurred following the release of its long-awaited annual report, delayed twice, revealing a reduced loss for Q4 2023. The report unveiled unsettling news – an internal review exposing “material weaknesses” in its financial practices.

The aftermath was grim as CC shares tumbled by 10.6% to $25.80 post-market.

The internal scrutiny unearthed disturbing revelations about the manipulation of vendor payments and accounts receivable collections by three high-ranking executives during Q4. It appeared that these actions were geared towards meeting free cash flow targets, intricately linked to their bonuses.

In the wake of this damning discovery, Chemours swiftly placed the trio – comprising its former Chief Executive Officer, Chief Financial Officer, and Principal Accounting Officer – on administrative leave in late February. The repercussions were severe, with the stock experiencing an unprecedented intraday plunge exceeding 30%.

On Wednesday, Chemours went public with the distressing news of four material weaknesses in its financial reporting after the internal review. This necessitated a revision of CC’s balance sheet as of December 31, 2022, and statement of cash flows for the years ended December 31, 2022, and 2021.

Further revelations from the review indicated “immaterial revisions” to CC’s quarterly financial statements for March, June, and September 2023. Notably, Chemours clarified that despite the deficiencies, there were no inaccuracies in its financial statements or disclosures.

The annual report detailed results for Q4, where the company posted a loss per share of 12 cents on revenue amounting to $1.36 billion. Analysts, anticipating a loss of 24 cents per share on revenue of $1.34 billion, were somewhat surprised by the figures.

While the net loss attributable to Chemours in Q4 contracted to $18 million from $97 million in the previous year, revenue saw a modest 1.7% year-over-year increase.

Additionally, the internal review pointed out that payments totaling around $100 million were delayed until Q1 2024, mainly to specific vendors whose dues were initially slated for Q4 2023. Conversely, the examination revealed the acceleration of receivables amounting to about $260 million, originally set for Q1 2024, into Q4 2023.

The review also brought to light similar, though less pronounced, actions undertaken in Q4 2022.

Taking Stock of the Situation